These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 18448443)

  • 21. [Clinical study of the month. Benefit/risk balance of postmenopausal estrogen-progestin treatment in peril in the Women's Health Initiative study: practical attitude of the clinician].
    Gaspard U; van den Brûle F; Pintiaux A; Foidart JM
    Rev Med Liege; 2002 Aug; 57(8):556-62. PubMed ID: 12405030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial.
    Shapiro S
    Climacteric; 2003 Dec; 6(4):302-10; discussion 310-3. PubMed ID: 15006251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer after use of estrogen plus progestin in postmenopausal women.
    Chlebowski RT; Kuller LH; Prentice RL; Stefanick ML; Manson JE; Gass M; Aragaki AK; Ockene JK; Lane DS; Sarto GE; Rajkovic A; Schenken R; Hendrix SL; Ravdin PM; Rohan TE; Yasmeen S; Anderson G;
    N Engl J Med; 2009 Feb; 360(6):573-87. PubMed ID: 19196674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of WHI conclusions and ACOG guidelines on clinical practice.
    Gass M
    Int J Fertil Womens Med; 2003; 48(3):106-10; discussion 137-8. PubMed ID: 12839140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
    McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
    J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perspectives on the Women's Health Initiative trial of hormone replacement therapy.
    Grimes DA; Lobo RA
    Obstet Gynecol; 2002 Dec; 100(6):1344-53. PubMed ID: 12468183
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pitfalls of the WHIs: Women's Health Initiative.
    Mastorakos G; Sakkas EG; Xydakis AM; Creatsas G
    Ann N Y Acad Sci; 2006 Dec; 1092():331-40. PubMed ID: 17308158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lessons learned from the WHI: HRT requires a cautious and individualized approach.
    Aubuchon M; Santoro N
    Geriatrics; 2004 Nov; 59(11):22-6. PubMed ID: 15615157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Postmenopausal hormone replacement therapy: scientific review.
    Nelson HD; Humphrey LL; Nygren P; Teutsch SM; Allan JD
    JAMA; 2002 Aug; 288(7):872-81. PubMed ID: 12186605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
    Nozaki M; Koera K; Nagata H; Nakano H
    J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative review of the risks and benefits of hormone replacement therapy regimens.
    Warren MP
    Am J Obstet Gynecol; 2004 Apr; 190(4):1141-67. PubMed ID: 15118656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Have we come full circle - or moved forward? The Women's Health Initiative 10 years on.
    Langer RD; Manson JE; Allison MA
    Climacteric; 2012 Jun; 15(3):206-12. PubMed ID: 22612605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of the Women's Health Initiative on discontinuation of postmenopausal hormone therapy: the Minnesota Heart Survey (2000-2002).
    Barber CA; Margolis K; Luepker RV; Arnett DK
    J Womens Health (Larchmt); 2004 Nov; 13(9):975-85. PubMed ID: 15665654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The evidence base for HRT: what can we believe?
    Langer RD
    Climacteric; 2017 Apr; 20(2):91-96. PubMed ID: 28281363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Menopausal hormone therapy, hormone receptor status, and lung cancer in women.
    Chlebowski RT
    Semin Oncol; 2009 Dec; 36(6):566-71. PubMed ID: 19995648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Women's Health Initiative estrogen plus progestin clinical trial: a study that does not allow establishing relevant clinical risks.
    Aedo S; Cavada G; Blümel JE; Chedraui P; Fica J; Barriga P; Brantes S; Irribarra C; Vallejo M; Campodónico Í
    Menopause; 2015 Dec; 22(12):1317-22. PubMed ID: 25968833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hormone therapy and breast cancer risk 10 years after the WHI.
    Gompel A; Santen RJ
    Climacteric; 2012 Jun; 15(3):241-9. PubMed ID: 22612610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication.
    Guay MP; Dragomir A; Pilon D; Moride Y; Perreault S
    Pharmacoepidemiol Drug Saf; 2007 Jan; 16(1):17-27. PubMed ID: 16794994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hormone replacement therapy and cancer.
    Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Menopause in 2004: "hormone replacement therapy" is not what it used to be anymore].
    Azoulay C
    Rev Med Interne; 2004 Nov; 25(11):806-15. PubMed ID: 15501350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.